Ilaris (canakinumab) — Highmark
Systemic Juvenile Idiopathic Arthritis (SJIA)
Initial criteria
- age ≥ 2 years
- diagnosis of systemic juvenile idiopathic arthritis (SJIA)
- prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- member is tolerating therapy AND has experienced disease improvement OR delayed disease progression